Brian Thomas, Metagenomi CEO

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Gene edit­ing com­pa­ny Metageno­mi has set a price range for its pro­posed ini­tial pub­lic of­fer­ing, mark­ing a key step for pre­clin­i­cal biotechs af­ter weeks of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.